Merck (MRK) stock climbed 10% to new highs after Phase 3 cancer vaccine trial success with Moderna. Analysts project $3B in sales by 2035. The post Merck (MRK) Stock Rockets 10% After Groundbreaking Cancer Vaccine Trial Success appeared first on Blockonomi.